Abstract

Downloaded from http://cvi.asm.org/ on April 14, 2021 by guest SPOTLIGHT crossm Article of Significant Interest Selected from This Issue by the Editors Plasmodium vivax CelTOS Vaccine and Challenge There is no licensed vaccine against the most widely distributed human malaria parasite, Plasmodium vivax. The preerythrocytic stage is a highly attractive target for vaccination, but there is a need to assess novel vaccine candidates, platforms, and adjuvants to improve efficacy. Alves et al. (e00501-16) evaluated the protective efficacy of the Plasmodium vivax cell-traversal protein for ookinetes and sporozoites (PvCelTOS) using four different vaccine platforms and a transgenic parasite expressing the P. vivax CelTOS. Efficacy, albeit modest, was Immunofluorescence analysis show- induced by an adenovirus-protein prime/boost regimen, and there was evidence of cross ing PvCelTOS antigen expression in protection against the P. falciparum CelTOS. chimeric P. berghei sporozoites. Copyright © 2017 American Society for Microbiology. All Rights Reserved. https://doi.org/10.1128/CVI.00065-17 April 2017 Volume 24 Issue 4 e00065-17 Clinical and Vaccine Immunology cvi.asm.org 1